PUBLISHER: Inkwood Research | PRODUCT CODE: 1142624
PUBLISHER: Inkwood Research | PRODUCT CODE: 1142624
Europe Cell Therapy Market Forecast 2022-2030
KEY FINDINGS
The Europe cell therapy market is expected to record a CAGR of 14.63% during the forecast period, 2022-2030. Several market players in the region are collaborating to develop cell therapies. Also, many cell therapies are gaining approval in Europe. However, technical issues restrict the widespread use of cell therapies in the region.
MARKET INSIGHTS
Germany, Spain, Italy, France, the United Kingdom, Poland, Belgium, and Rest of Europe are evaluated for the Europe cell therapy market growth assessment. In Germany, there is growing adoption of advanced treatment techniques like cell therapy for treating chronic diseases like diabetes and cancer. Also, many organizations and private clinics offer cell therapy-related services and support. For instance, the German Stem Cell Network (GSCN) is actively engaged in developing stem cell research. Additionally, healthcare providers like CBC Health Munich, German International Clinic, PHI Orthopedic Physiotherapy Center, etc., offer stem cell therapy for different chronic diseases like rheumatoid arthritis, optic nerve neuritis, and retinopathy.
Furthermore, the growing partnerships among international players boost the market growth. For instance, apceth Biopharma GmbH and Hitachi Chemical Advanced Therapeutics Solutions LLC expanded their relationship with bluebird bio in November 2020 through long-term development and manufacturing service agreements for commercial and clinical supply for multiple therapies.
In Italy, government agencies are involved in developing advanced healthcare technologies. For instance, the Italian Medicines Agency (AIFA) declared in August 2019 that it would be reimbursing CAR-T cell therapy Kymriah as part of the new reimbursement approach. Such developments are expected to offer growth opportunities in these countries.
COMPETITIVE INSIGHTS
Some of the leading companies in the market are: Gilead Sciences Inc, Smith & Nephew Plc, Cells for Cells SA, JCR Pharmaceuticals Co Ltd, etc.
Our report offerings include:
- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
- 1.1. STUDY OBJECTIVES
- 1.2. SCOPE OF STUDY
- 1.3. METHODOLOGY
- 1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
- 2.1. MARKET SIZE & ESTIMATES
- 2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
- 3.1. KEY DRIVERS
- 3.1.1. INCREASING CELLULAR THERAPY CLINICAL TRIALS
- 3.1.2. GROWTH OF REGENERATIVE MEDICINE
- 3.1.3. HIGH PREVALENCE OF CHRONIC DISEASES
- 3.2. KEY RESTRAINTS
- 3.2.1. INCREASING SKILLS GAP
- 3.2.2. HIGH COSTS
4. KEY ANALYTICS
- 4.1. IMPACT OF COVID-19 ON CELL THERAPY MARKET
- 4.2. KEY MARKET TRENDS
- 4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
- 4.4. REGULATORY FRAMEWORK
- 4.5. OPPORTUNITY MATRIX
- 4.6. VENDOR LANDSCAPE
5. MARKET BY CELL TYPE
- 5.1. STEM CELL
- 5.1.1. BONE MARROW
- 5.1.2. BLOOD
- 5.1.3. UMBILICAL CORD-DERIVED STEM CELL
- 5.1.4. ADIPOSE-DERIVED STEM CELL
- 5.1.5. OTHERS
- 5.2. NON-STEM CELL
6. MARKET BY THERAPY TYPE
- 6.1. AUTOLOGOUS
- 6.2. ALLOGENEIC
7. MARKET BY THERAPEUTIC APPLICATION
- 7.1. MALIGNANCIES
- 7.2. MUSCULOSKELETAL DISORDERS
- 7.3. AUTOIMMUNE DISORDERS
- 7.4. DERMATOLOGY
- 7.5. OTHER APPLICATIONS
8. MARKET BY END-USER
- 8.1. HOSPITALS & CLINICS
- 8.2. ACADEMIC & RESEARCH INSTITUTES
9. GEOGRAPHICAL ANALYSIS
- 9.1. EUROPE
- 9.1.1. MARKET SIZE & ESTIMATES
- 9.1.2. KEY DRIVERS
- 9.1.3. KEY CHALLENGES
- 9.1.4. KEY PLAYERS
- 9.1.5. COUNTRY ANALYSIS
- 9.1.5.1. UNITED KINGDOM
- 9.1.5.2. GERMANY
- 9.1.5.3. FRANCE
- 9.1.5.4. ITALY
- 9.1.5.5. SPAIN
- 9.1.5.6. BELGIUM
- 9.1.5.7. POLAND
- 9.1.5.8. REST OF EUROPE
10. COMPETITIVE LANDSCAPE
- 10.1. KEY STRATEGIC DEVELOPMENTS
- 10.1.1. MERGERS & ACQUISITIONS
- 10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 10.1.3. PARTNERSHIPS & AGREEMENTS
- 10.1.4. BUSINESS EXPANSIONS
- 10.2. COMPANY PROFILES
- 10.2.1. ANTEROGEN CO LTD
- 10.2.2. BRISTOL MYERS SQUIBB COMPANY
- 10.2.3. CELLS FOR CELLS SA
- 10.2.4. GILEAD SCIENCES INC
- 10.2.5. JCR PHARMACEUTICALS CO LTD
- 10.2.6. KOLON TISSUEGENE INC
- 10.2.7. MEDIPOST CO LTD
- 10.2.8. MESOBLAST LIMITED
- 10.2.9. NUVASIVE INC
- 10.2.10. SMITH & NEPHEW PLC
- 10.2.11. STEMEDICA CELL TECHNOLOGIES INC
- 10.2.12. VERICEL CORPORATION
LIST OF TABLES
- TABLE 1: MARKET SNAPSHOT - CELL THERAPY
- TABLE 2: REGULATORY FRAMEWORK
- TABLE 3: EUROPE CELL THERAPY MARKET, BY CELL TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 4: EUROPE CELL THERAPY MARKET, BY CELL TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 5: EUROPE CELL THERAPY MARKET, BY STEM CELL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 6: EUROPE CELL THERAPY MARKET, BY STEM CELL, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 7: EUROPE CELL THERAPY MARKET, BY THERAPY TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 8: EUROPE CELL THERAPY MARKET, BY THERAPY TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 9: EUROPE CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 10: EUROPE CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 11: EUROPE CELL THERAPY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 12: EUROPE CELL THERAPY MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 13: EUROPE CELL THERAPY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 14: EUROPE CELL THERAPY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 15: KEY PLAYERS IN EUROPE CELL THERAPY MARKET
- TABLE 16: LIST OF MERGERS & ACQUISITIONS
- TABLE 17: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
- TABLE 18: LIST OF PARTNERSHIPS & AGREEMENTS
- TABLE 19: LIST OF BUSINESS EXPANSIONS
LIST OF FIGURES
- FIGURE 1: KEY MARKET TRENDS
- FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
- FIGURE 3: OPPORTUNITY MATRIX
- FIGURE 4: VENDOR LANDSCAPE
- FIGURE 5: EUROPE CELL THERAPY MARKET, GROWTH POTENTIAL, BY CELL TYPE, IN 2021
- FIGURE 6: EUROPE CELL THERAPY MARKET, BY STEM CELL, 2022-2030 (IN $ MILLION)
- FIGURE 7: EUROPE CELL THERAPY MARKET, GROWTH POTENTIAL, BY STEM CELL, IN 2021
- FIGURE 8: EUROPE CELL THERAPY MARKET, BY BONE MARROW, 2022-2030 (IN $ MILLION)
- FIGURE 9: EUROPE CELL THERAPY MARKET, BY BLOOD, 2022-2030 (IN $ MILLION)
- FIGURE 10: EUROPE CELL THERAPY MARKET, BY UMBILICAL CORD-DERIVED STEM CELL, 2022-2030 (IN $ MILLION)
- FIGURE 11: EUROPE CELL THERAPY MARKET, BY ADIPOSE-DERIVED STEM CELL, 2022-2030 (IN $ MILLION)
- FIGURE 12: EUROPE CELL THERAPY MARKET, BY OTHERS, 2022-2030 (IN $ MILLION)
- FIGURE 13: EUROPE CELL THERAPY MARKET, BY NON-STEM CELL, 2022-2030 (IN $ MILLION)
- FIGURE 14: EUROPE CELL THERAPY MARKET, GROWTH POTENTIAL, BY THERAPY TYPE, IN 2021
- FIGURE 15: EUROPE CELL THERAPY MARKET, BY AUTOLOGOUS, 2022-2030 (IN $ MILLION)
- FIGURE 16: EUROPE CELL THERAPY MARKET, BY ALLOGENEIC, 2022-2030 (IN $ MILLION)
- FIGURE 17: EUROPE CELL THERAPY MARKET, GROWTH POTENTIAL, BY THERAPEUTIC APPLICATION, IN 2021
- FIGURE 18: EUROPE CELL THERAPY MARKET, BY MALIGNANCIES, 2022-2030 (IN $ MILLION)
- FIGURE 19: EUROPE CELL THERAPY MARKET, BY MUSCULOSKELETAL DISORDERS, 2022-2030 (IN $ MILLION)
- FIGURE 20: EUROPE CELL THERAPY MARKET, BY AUTOIMMUNE DISORDERS, 2022-2030 (IN $ MILLION)
- FIGURE 21: EUROPE CELL THERAPY MARKET, BY DERMATOLOGY, 2022-2030 (IN $ MILLION)
- FIGURE 22: EUROPE CELL THERAPY MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)
- FIGURE 23: EUROPE CELL THERAPY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
- FIGURE 24: EUROPE CELL THERAPY MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)
- FIGURE 25: EUROPE CELL THERAPY MARKET, BY ACADEMIC & RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)
- FIGURE 26: EUROPE CELL THERAPY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
- FIGURE 27: UNITED KINGDOM CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 28: GERMANY CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 29: FRANCE CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 30: ITALY CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 31: SPAIN CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 32: BELGIUM CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 33: POLAND CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 34: REST OF EUROPE CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
